Skin Treatment for Immuno Disorders: 82.8% of denials overturned
In 58 California IMR decisions from 2007 to 2025, reviewers overturned 48 (82.8%). In the last five years: 84.4% of 45. 36 were medical-necessity disputes, 22 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 18 | 88.9% |
| 2022 | 6 | 100.0% |
| 2023 | 13 | 76.9% |
| 2024 | 3 | 66.7% |
| 2025 | 5 | 80.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 28 | 85.7% | 82.8% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 23 | 82.6% | 82.8% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 4 | 0.0% | 82.8% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 3 | 100.0% | 82.8% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 3 | 0.0% | 82.8% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 3 | 100.0% | 82.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a rituximab infusion. Findings: The physician reviewer found that U.S. Food and Drug Administration (FDA) approves using rituximab to treat pemphigus vulgaris. Severe pemphigus vulgaris may lead to significant side effects, particularly when mucosal surfaces are involved. Treatment of severe pemphigus vulgaris should be individualized based on …”
“Nature of Statutory Criteria/Case Summary: A patient’s parent has requested authorization and coverage for Litfulo 50 mg capsules.Findings: The physician reviewer found that Current medical literature evaluating the efficacy and safety of ritlecitinib for the treatment of alopecia areata demonstrates clinician-reported efficacy, patient-reported improvement, and an acceptable safety profile through week 48 in adolescents aged 12 through 17 years with …”
“The physician reviewer found that a patient has requested authorization and coverage for Rinvoq. This patient has failed multiple standard and guideline-based treatments, such as phototherapy, potent topical steroids, and tacrolimus, without improvement. The condition continues to progress. The patient has extensive disease beyond the range apropiate for topical therapy, above the maximum surface area recommended for currently approved topical …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Opzelura cream.The records indicate that this patient is being treated with topical Opzelura for eyebrows with some improvement. The patient was previously treated with other agents. Alopecia areata is an autoimmune medical condition and must be treated accordingly. Clinical trials for Janus …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Skin Treatment denials for Immuno Disorders overturned?
In 58 California IMR decisions from 2007 to 2025, reviewers overturned 48 (82.8%). In the last five years: 84.4% of 45. 36 were medical-necessity disputes, 22 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.